2. Signaling Pathways
  3. Apoptosis
  4. c-Myc

c-Myc

Myc

c-Myc

Related Products

PDF 0.13 MB

The transcription factor c-Myc is a member of the basic helix-loop-helix leucinezipper (bHLHZip) protein family. The target genes of the c-MYC protein participate in different cellular functions, including cell cycle, survival, protein synthesis, cell adhesion, and micro-RNA expression. c-Myc is also one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS) cells and is implicated in maintaining cancer stem-like cells (CSCs). Most biological functions of c-Myc require heterodimerization with its activation partner Max.

c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. Deregulated expression of c-MYC caused by gene amplification, retroviral insertion, or chromosomal translocation is associated with tumorigenesis. c-Myc has been identified as a highly promising target for cancer therapy.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146660
    BRD4 Inhibitor-18
    		Inhibitor
    BRD4 Inhibitor-18 is a highly potent BRD4 inhibitor with an IC50 value of 110 nM. BRD4 Inhibitor-18 has a hydrophobic acetylcyclopentanyl side chain. BRD4 Inhibitor-18 can significantly suppress the proliferation of MV-4-11 cells with high BRD4 level. BRD4 Inhibitor-18 has apoptosis-promoting and G0/G1 cycle-arresting activity.
    BRD4 Inhibitor-18
  • HY-17381A
    Idarubicin
    		Inhibitor
    Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts.
    Idarubicin
  • HY-125978
    JY-3-094
    		Inhibitor
    JY-3-094 is a Myc inhibitor that inhibits Myc-Max heterodimer formation (IC50: 33 μM).
    JY-3-094
  • HY-138071
    8α-Tigloyloxyhirsutinolide 13-O-acetate
    		Inhibitor
    8α-Tigloyloxyhirsutinolide 13-O-acetate (8αTGH) is a potent and orally active STAT3 inhibitor. 8α-Tigloyloxyhirsutinolide 13-O-acetate induces early oxidative stress and pyroptosis, and late DNA damage, cell cycle arrest, apoptosis in the TNBC cells. 8α-Tigloyloxyhirsutinolide 13-O-acetate suppresses tumor cell growth in vitro and tumor growth in vivo.
    8α-Tigloyloxyhirsutinolide 13-O-acetate
  • HY-156084
    LL-K9-3
    		Inhibitor
    LL-K9-3 is a potent small-molecule degrader of CDK9-cyclin T1. LL-K9-3 has anti-proliferative and pro-apoptotic activities and suppresses downstream signaling of CDK9 and AR. Moreover, LL-K9-3 inhibits AR and Myc-driven oncogenic transcriptional programs.
    LL-K9-3
  • HY-143235
    BRD4 Inhibitor-15
    		Inhibitor
    BRD4 Inhibitor-15 (compound 13) is a potent BRD4 inhibitor, with an IC50 of 18 nM. BRD4 Inhibitor-15 induces apoptosis of 22RV1 cells by regulating Bcl-2/Bax proteins and activating caspase-3 signaling pathway. BRD4 Inhibitor-15 down-regulates the c-Myc level in 22RV1 cells. BRD4 Inhibitor-15 can be used for prostate cancer research.
    BRD4 Inhibitor-15
  • HY-162469
    6K465
    		Inhibitor
    6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of c-MYC and N-MYC oncoproteins, demonstrating anticancer activity.
    6K465
  • HY-155507
    c-Myc inhibitor 11
    		Inhibitor
    c-Myc inhibitor 11 (Compound 67e) is a c-MYC inhibitor (pEC50: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research.
    c-Myc inhibitor 11
  • HY-131203
    PROTAC BRD4 Degrader-6
    		Inhibitor
    PROTAC BRD4 Degrader-6 (compound 32a) is a potent small-molecule BRD4 degrader with IC50 value of 2.7 nM for BRD4 BD1. PROTAC BRD4 Degrader-6 potently degrades BRD4 protein and inhibits the expression of c-Myc. PROTAC BRD4 Degrader-6 inhibits the proliferation of pancreatic cancer cell line BxPC3 and induces apoptosis. PROTAC BRD4 Degrader-6 can be used for human pancreatic cancer research.
    PROTAC BRD4 Degrader-6
  • HY-156673
    m-Se3
    		Inhibitor
    m-Se3 is a potent and selective c-MYC transcription inhibitor that can inhibit tumor growth and has anti-cancer activity.
    m-Se3
  • HY-N2302R
    Fucoxanthin (Standard)
    Fucoxanthin (Standard) is the analytical standard of Fucoxanthin. This product is intended for research and analytical applications. Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
    Fucoxanthin (Standard)
  • HY-160549
    c-Myc inhibitor 14
    		Inhibitor
    c-Myc inhibitor 14 (Compound 13A) is a c-Myc protein inhibitor. The IC50 value of HL60 inhibitor is <100 nM. c-Myc inhibitor 14 shows antitumor activity.
    c-Myc inhibitor 14
  • HY-125090
    PHA-680626
    		Inhibitor
    PHA-680626 is an effective inhibitor of the interaction between Aurora-A and N-Myc. PHA-680626 inhibits kinase activity of AURKA and Bcr-Abl, and induces N-Myc degradation. PHA-680626 decreases phosphorylation of CrkL and histone H3. PHA-680626 shows anti-proliferative and pro-apoptotic activity on Imatinib (HY-15463)-resistant chronic myeloid leukemia cell lines and primary CD34+ cells.
    PHA-680626
  • HY-143471
    WNY0824
    		Inhibitor
    WNY0824 (PLK1/BRD4-IN-1) is an orally active dual inhibitor of PLK1 and BET protein families, with IC50 values ​​of 22, 402.5, 150.7, 103.9, and 311.9 nmol/L for PLK1, BRD2, BRD3, BRD4, and BRDT, respectively. WNY0824 induces cell cycle arrest and apoptosis by inhibiting AR- and MYC-mediated transcriptional processes. In addition, WNY0824 also inhibits tumor growth in Enzalutamide (HY-70002) resistant CRPC xenograft tumor models.
    WNY0824
  • HY-154839
    c-Myc inhibitor 10
    		Inhibitor
    c-Myc inhibitor 10 (compound 17), a c-Myc inhibitor, exhibits increased cellular potency, consistent with an increase in permeability with methylation of the morpholine nitrogen.
    c-Myc inhibitor 10
  • HY-121444
    MYRA-A
    		Inhibitor
    MYRA-A is a potent apoptosis inducer in a Myc-dependent manner. MYRA-A inhibits Myc transactivation and interferes with the DNA-binding activity of Myc family proteins. MYRA-A inhibits cell viability.
    MYRA-A
  • HY-161127
    NT-B2R
    		Inhibitor
    NT-B2R is a potent MYC inhibitor. NT-B2R inhibited MYC transcriptional activity and cell proliferation.
    NT-B2R
  • HY-148838
    c-Myc inhibitor 8
    		Inhibitor
    c-Myc inhibitor 8 (compound 56) is a c-Myc inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research.
    c-Myc inhibitor 8
  • HY-155508
    c-Myc inhibitor 12
    		Inhibitor
    c-Myc inhibitor 12 (compound 67h) is an inhibitor of c-Myc with a pEC50 of 6.4.
    c-Myc inhibitor 12
  • HY-161826
    Antitumor agent-174
    		Inhibitor
    Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity.
    Antitumor agent-174
Cat. No. Product Name / Synonyms Application Reactivity